Skip to main content
. 2010 Aug 3;15(8):862–872. doi: 10.1634/theoncologist.2009-0186

Figure 2.

Figure 2.

RADIANT: Phase III trial of adjuvant erlotinib after surgical resection of stage IB–IIIA EGFR+ NSCLC.

Abbreviations: DFS, disease-free survival; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; OS, overall survival; RADIANT, Randomized Double-Blind Trial in Adjuvant NSCLC with Tarceva®.